Keri A. Streby

Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients

Keri A. Streby, James I. Geller, Mark A. Currier et al. · Clinical Cancer Research · 2017 · 137 citations · Full text

Medicine, Immunology, Oncology +16

First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial

Keri A. Streby, Mark A. Currier, Melinda Triplet et al. · Molecular Therapy · 2019 · 61 citations · Full text

Pharmacy, Oncology, Pharmacology +16

Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor

Benjamin Lerman, Yimei Li, Cecilia Carlowicz et al. · Journal of Clinical Oncology · 2022 · 42 citations

Medicine, Oncology, Pharmacotherapy +13

VEGF Blockade Enables Oncolytic Cancer Virotherapy in Part by Modulating Intratumoral Myeloid Cells

Mark A. Currier, Francis K. Eshun, Allyson Sholl et al. · Molecular Therapy · 2013 · 40 citations · Full text

Life Sciences, Immunology, Oncology +17

Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation

Mark A. Currier, Les Sprague, Tilat A. Rizvi et al. · Oncotarget · 2017 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17